IMR Press / FBL / Volume 28 / Issue 9 / DOI: 10.31083/j.fbl2809198
Open Access Review
Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis
Show Less
1 Laboratory of Applied Biochemistry, Faculté des sciences de la nature et de la vie, Université Frères Mentouri Constantine 1, 25000 Constantine, Algeria
2 Unité de Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques, Université des Frères MentouriConstantine, 25000 Constantine, Algeria
3 Département de Chimie, Faculté des Sciences, Université Mohammed Boudiaf-M’sila, 28000 M’Sila, Algeria
4 Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy
5 Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, 2713 Doha, Qatar
6 Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, 2713 Doha, Qatar
7 Department of Medical Laboratory Sciences, College of Health Sciences and Sharjah Institute for Medical Research, University of Sharjah, 27272Sharjah, United Arab Emirates
*Correspondence: (Ali H. Eid); (Gianfranco Pintus)
Front. Biosci. (Landmark Ed) 2023, 28(9), 198;
Submitted: 30 April 2023 | Revised: 27 July 2023 | Accepted: 1 August 2023 | Published: 14 September 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Pulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases, which are characterized by increased alveolar wall thickness, excessive scarring, and aberrant extracellular matrix restructuring that, ultimately, affect lung compliance and capacity. As a result of its broad range of biological activities, including antioxidant, anti-inflammatory, antiapoptotic, and many others, resveratrol has been shown to be an effective treatment for respiratory system diseases, including interstitial lung disease, infectious diseases, and lung cancer. This work reviews the known molecular therapeutic targets of resveratrol and its potential mechanisms of action in attenuating PF in respiratory diseases, including cancer, COVID-19, interstitial lung diseases (ILDs) of known etiologies, idiopathic interstitial pneumonia, and ILDs associated with systemic disorders, such as rheumatoid arthritis, systemic sclerosis, Schrödinger’s syndrome, systemic lupus erythematosus, and pulmonary hypertension. The current issues and controversies related to the possible use of resveratrol as a pharmaceutical drug or supplement are also discussed.

pulmonary fibrosis
interstitial lung diseases
Progetto Fondazione di Sardegna-Bando 2022–2023
European Union - NextGenerationEU
Fig. 1.
Back to top